Efficacy of a Plasmodium vivax malaria vaccine using ChAd63 and modified vaccinia ankara expressing thrombospondin-related anonymous protein as assessed with transgenic Plasmodium berghei parasites

Infection and Immunity

Volumn 82, Issue 3, 2014, Pages 1277-1286

  Bauza, Karolis ^a   Malinauskas, Tomas ^b   Pfander, Claudia ^c   Anar, Burcu ^c   Yvonne Jones, E ^b   Billker, Oliver ^c   Hill, Adrian V S ^a   Reyes Sandoval, Arturo ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c WELLCOME TRUST SANGER INSTITUTE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRIDAE; ANIMALS; ANTIBODIES, PROTOZOAN; ANTIGENS, PROTOZOAN; CD8-POSITIVE T-LYMPHOCYTES; CULICIDAE; FEMALE; GENETIC VECTORS; MALARIA VACCINES; MALARIA, VIVAX; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MICE, INBRED ICR; PAN TROGLODYTES; PLASMODIUM BERGHEI; PLASMODIUM VIVAX; PROTOZOAN PROTEINS; VACCINIA; VACCINIA VIRUS;

EID: 84894249523     PISSN: 00199567     EISSN: 10985522     Source Type: Journal    
DOI: 10.1128/IAI.01187-13     Document Type: Article

References (34)

1. Guerra CA, Howes RE, Patil AP, Gething PW, Van Boeckel TP, Temperley WH, Kabaria CW, Tatem AJ, Manh BH, Elyazar IR, Baird JK, Snow RW, Hay SI. 2010. The international limits and population at risk of Plasmodium vivax transmission in 2009. PLoS Negl. Trop. Dis. 4:e774. http://dx.doi.org/10.1371/journal.pntd.0000774.
2. Price RN, Tjitra E, Guerra CA, Yeung S, White NJ, Anstey NM. 2007. Vivax malaria: neglected and not benign. Am. J. Trop. Med. Hyg. 77:79-87.
3. Arevalo-Herrera M, Vera O, Castellanos A, Cespedes N, Soto L, Corradin G, Herrera S. 2011. Preclinical vaccine study of Plasmodium vivax circumsporozoite protein derived-synthetic polypeptides formulated in montanide ISA 720 and montanide ISA 51 adjuvants. Am. J. Trop. Med. Hyg. 84:21-27. http://dx.doi.org/10.4269/ajtmh.2011.10-0110.
4. Herrera S, Solarte Y, Jordan-Villegas A, Echavarria JF, Rocha L, Palacios R, Ramirez O, Velez JD, Epstein JE, Richie TL, Arevalo-Herrera M.2011. Consistent safety and infectivity in sporozoite challenge model of Plasmodium vivax in malaria-naive human volunteers. Am. J. Trop. Med. Hyg. 84:4-11. http://dx.doi.org/10.4269/ajtmh.2011.09-0498.
5. Jordan-Villegas A, Perdomo AB, Epstein JE, Lopez J, Castellanos A, Manzano MR, Hernandez MA, Soto L, Mendez F, Richie TL, Hoffman SL, Arevalo-Herrera M, Herrera S. 2011. Immune responses and protection of Aotus monkeys immunized with irradiated Plasmodium vivax sporozoites. Am. J. Trop. Med. Hyg. 84:43-50. http://dx.doi.org/10.4269 /ajtmh.2011.09-0759.
6. Ramjanee S, Robertson JS, Franke-Fayard B, Sinha R, Waters AP, Janse CJ, Wu Y, Blagborough AM, Saul A, Sinden RE. 2007. The use of transgenic Plasmodium berghei expressing the Plasmodium vivax antigen P25 to determine the transmission-blocking activity of sera from malaria vaccine trials. Vaccine 25:886-894. http://dx.doi.org/10.1016/j.vaccine .2006.09.035.
7. Espinosa DA, Yadava A, Angov E, Maurizio PL, Ockenhouse CF, Zavala F. 2013. Development of a chimeric Plasmodium berghei strain expressing the repeat region of the P. vivax circumsporozoite protein for in vivo evaluation of vaccine efficacy. Infect. Immun. 81:2882-2887. http: //dx.doi.org/10.1128/IAI.00461-13.
8. Kappe SH, Buscaglia CA, Nussenzweig V. 2004. Plasmodium sporozoite molecular cell biology. Annu. Rev. Cell Dev. Biol. 20:29-59. http://dx.doi .org/10.1146/annurev.cellbio.20.011603.150935.
9. Reyes-Sandoval A, Berthoud T, Alder N, Siani L, Gilbert SC, Nicosia A, Colloca S, Cortese R, Hill AV. 2010. Prime-boost immunization with adenoviral andmodifiedvaccinia virusAnkaravectorsenhancesthedurabilityandpolyfunctionality of protective malaria CD8+ T-cell responses. Infect. Immun. 78:145-153. http://dx.doi.org/10.1128/IAI.00740-09.
10. Reyes-Sandoval A, Sridhar S, Berthoud T, Moore AC, Harty JT, Gilbert SC, Gao G, Ertl HC, Wilson JC, Hill AV. 2008. Single-dose immunogenicity and protective efficacy of simian adenoviral vectors against Plasmodium berghei. Eur. J. Immunol. 38:732-741. http://dx.doi.org/10.1002 /eji.200737672.
11. Webster DP, Dunachie S, Vuola JM, Berthoud T, Keating S, Laidlaw SM, McConkey SJ, Poulton I, Andrews L, Andersen RF, Bejon P, Butcher G, Sinden R, Skinner MA, Gilbert SC, Hill AV. 2005. Enhanced T cell-mediated protection against malaria in human challenges by using the recombinant poxviruses FP9 and modified vaccinia virus Ankara. Proc. Natl. Acad. Sci. U. S. A. 102:4836-4841. http://dx.doi.org/10.1073 /pnas.0406381102.
12. Aricescu AR, Lu W, Jones EY. 2006. A time-and cost-efficient system for high-level protein production in mammalian cells. Acta Crystallogr. D Biol. Crystallogr. 62:1243-1250. http://dx.doi.org/10.1107/S0907444906029799.
13. Godiska R, Mead D, Dhodda V, Wu C, Hochstein R, Karsi A, Usdin K, Entezam A, Ravin N. 2010. Linear plasmid vector for cloning of repetitive or unstable sequences in Escherichia coli. Nucleic Acids Res. 38:e88. http: //dx.doi.org/10.1093/nar/gkp1181.
14. Pfander C, Anar B, Schwach F, Otto TD, Brochet M, Volkmann K, Quail MA, Pain A, Rosen B, Skarnes W, Rayner JC, Billker O. 2011. A scalable pipeline for highly effective genetic modification of a malaria parasite. Nat. Methods 8:1078-1082. http://dx.doi.org/10.1038/nmeth.1742.
15. Zhang Y, Buchholz F, Muyrers JP, Stewart AF. 1998. A new logic for DNA engineering using recombination in Escherichia coli. Nat. Genet. 20:123-128. http://dx.doi.org/10.1038/2417.
16. Pfander C, Anar B, Brochet M, Rayner JC, Billker O. 2013. Recombination-mediated genetic engineering of Plasmodium berghei DNA. Methods Mol. Biol. 923:127-138. http://dx.doi.org/10.1007/978-1-62703-026-7_8.
17. Wang J, Sarov M, Rientjes J, Fu J, Hollak H, Kranz H, Xie W, Stewart AF, Zhang Y. 2006. An improved recombineering approach by adding RecA to lambda Red recombination. Mol. Biotechnol. 32:43-53. http://dx .doi.org/10.1385/MB:32:1:043.
18. Orr RY, Philip N, Waters AP. 2012. Improved negative selection protocol for Plasmodium berghei in the rodent malarial model. Malar. J. 11:103. http://dx.doi.org/10.1186/1475-2875-11-103.
19. Roederer M, Nozzi JL, Nason MX. 2011. SPICE: exploration and analysis of post-cytometric complex multivariate datasets. Cytometry A 79:167-174. http://dx.doi.org/10.1002/cyto.a.21015.
20. Draper SJ, Goodman AL, Biswas S, Forbes EK, Moore AC, Gilbert SC, Hill AV. 2009. Recombinant viral vaccines expressing merozoite surface protein-1 induce antibody-and T cell-mediated multistage protection against malaria. Cell Host Microbe 5:95-105. http://dx.doi.org/10.1016/j .chom.2008.12.004.
21. Yoshida N, Nussenzweig RS, Potocnjak P, Nussenzweig V, Aikawa M.1980. Hybridoma produces protective antibodies directed against the sporozoite stage of malaria parasite. Science 207:71-73. http://dx.doi.org /10.1126/science.6985745.
22. Reyes-Sandoval A, Wyllie DH, Bauza K, Milicic A, Forbes EK, Rollier CS, Hill AV. 2011. CD8+ T effector memory cells protect against liverstage malaria. J. Immunol. 187:1347-1357. http://dx.doi.org/10.4049 /jimmunol.1100302.
23. Thathy V, Fujioka H, Gantt S, Nussenzweig R, Nussenzweig V, Menard R. 2002. Levels of circumsporozoite protein in the Plasmodium oocyst determine sporozoite morphology. EMBO J. 21:1586-1596. http://dx.doi .org/10.1093/emboj/21.7.1586.
24. Wengelnik K, Spaccapelo R, Naitza S, Robson KJ, Janse CJ, Bistoni F, Waters AP, Crisanti A. 1999. The A-domain and the thrombospondinrelated motif of Plasmodium falciparum TRAP are implicated in the invasion process of mosquito salivary glands. EMBO J. 18:5195-5204. http: //dx.doi.org/10.1093/emboj/18.19.5195.
25. O'Hara GA, Duncan CJ, Ewer KJ, Collins KA, Elias SC, Halstead FD, Goodman AL, Edwards NJ, Reyes-Sandoval A, Bird P, Rowland R, Sheehy SH, Poulton ID, Hutchings C, Todryk S, Andrews L, Folgori A, Berrie E, Moyle S, Nicosia A, Colloca S, Cortese R, Siani L, Lawrie AM, Gilbert SC, Hill AV. 2012. Clinical assessment of a recombinant simian adenovirus ChAd63: a potent new vaccine vector. J. Infect. Dis. 205:772-781. http://dx.doi.org/10.1093/infdis/jir850.
26. Song G, Koksal AC, Lu C, Springer TA. 2012. Shape change in the receptor for gliding motility in Plasmodium sporozoites. Proc. Natl. Acad. Sci. U. S. A. 109: 21420-21425. http://dx.doi.org/10.1073/pnas.1218581109.
27. Aldrich C, Magini A, Emiliani C, Dottorini T, Bistoni F, Crisanti A, Spaccapelo R. 2012. Roles of the amino terminal region and repeat region of the Plasmodium berghei circumsporozoite protein in parasite infectivity. PLoS One 7:e32524. http://dx.doi.org/10.1371/journal.pone.0032524.
28. Khusmith S, Charoenvit Y, Kumar S, Sedegah M, Beaudoin RL, Hoffman SL. 1991. Protection against malaria by vaccination with sporozoite surface protein 2 plus CS protein. Science 252:715-718. http://dx.doi.org /10.1126/science.1827210.
29. Khusmith S, Sedegah M, Hoffman SL. 1994. Complete protection against Plasmodium yoelii by adoptive transfer of a CD8+ cytotoxic T-cell clone recognizing sporozoite surface protein 2. Infect. Immun. 62:2979-2983.
30. Dodoo D, Hollingdale MR, Anum D, Koram KA, Gyan B, Akanmori BD, Ocran J, Adu-Amankwah S, Geneshan H, Abot E, Legano J, Banania G, Sayo R, Brambilla D, Kumar S, Doolan DL, Rogers WO, Epstein J, Richie TL, Sedegah M. 2011. Measuring naturally acquired immune responses to candidate malaria vaccine antigens in Ghanaian adults. Malar. J. 10:168. http://dx.doi.org/10.1186/1475-2875-10-168.
31. Charoenvit Y, Fallarme V, Rogers WO, Sacci JB, Jr, Kaur M, Aguiar JC, Yuan LF, Corradin G, Andersen E, Wizel B, Houghten RA, Oloo A, De la Vega P, Hoffman SL. 1997. Development of two monoclonal antibodies against Plasmodium falciparum sporozoite surface protein 2 and mapping of B-cell epitopes. Infect. Immun. 65:3430-3437.
32. Rogers WO, Malik A, Mellouk S, Nakamura K, Rogers MD, Szarfman A, Gordon DM, Nussler AK, Aikawa M, Hoffman SL. 1992. Characterization of Plasmodium falciparum sporozoite surface protein 2. Proc. Natl. Acad. Sci. U. S. A. 89:9176-9180. http://dx.doi.org/10.1073/pnas.89 .19.9176.
33. Capone S, Reyes-Sandoval A, Naddeo M, Siani L, Ammendola V, Rollier CS, Nicosia A, Colloca S, Cortese R, Folgori A, Hill AV. 2010. Immune responses against a liver-stage malaria antigen induced by simian adenoviral vector AdCh63 and MVA prime-boost immunisation in nonhuman primates. Vaccine 29:256-265. http://dx.doi.org/10.1016/j .vaccine.2010.10.041.
34. Jordan-Villegas A, Zapata JC, Perdomo AB, Quintero GE, Solarte Y, Arevalo-Herrera M, Herrera S. 2005. Aotus lemurinus griseimembra monkeys: a suitable model for Plasmodium vivax sporozoite infection. Am. J. Trop. Med. Hyg. 73:10-15.